Lymphoid gene expression supports neuroprotective microglia function.
Microglial function in Alzheimer's disease may be influenced by the transcription factor PU.1 and the receptor CD28, suggesting new avenues for immunotherapy. However, findings from mouse models require cautious interpretation when considering human applications.
Where it sits
this study against the rest of the lixisenatide corpusSummary and findings
This study investigates the role of microglia in Alzheimer's disease (AD) pathology, focusing on the transcription factor PU.1 and its regulation of immunoregulatory lymphoid receptor proteins. The research was conducted in mice, examining the effects of CD28 deficiency in microglia on amyloid plaque load and neuroinflammation. The findings suggest a potential link between microglial function and AD progression.
Abstract
Microglia, the innate immune cells of the brain, play a defining role in the progression of Alzheimer's disease (AD)<sup>1</sup>. The microglial response to amyloid plaques in AD can range from neuroprotective to neurotoxic<sup>2</sup>. Here we show that the protective function of microglia is governed by the transcription factor PU.1, which becomes downregulated following microglial contact with plaques. Lowering PU.1 expression in microglia reduces the severity of amyloid disease pathology in mice and is linked to the expression of immunoregulatory lymphoid receptor proteins, particularly CD28, a surface receptor that is critical for T cell activation<sup>3,4</sup>. Microglia-specific deficiency in CD28, which is expressed by a small subset of plaque-associated PU.1<sup>low</sup> microglia, promotes a broad inflammatory microglial state that is associated with increased amyloid plaque load. Our findings indicate that PU.1<sup>low</sup> CD28-expressing microglia may operate as suppressive microglia that mitigate the progression of AD by reducing the severity of neuroinflammation. This role of CD28 and potentially other lymphoid co-stimulatory and co-inhibitory receptor proteins in governing microglial responses in AD points to possible immunotherapy approaches for treating the disease by promoting protective microglial functions.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.